Overview

Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer

Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to verify if the addition of enzalutamide to docetaxel is able to improve the disease control in first line CRPC patients.
Phase:
Phase 2
Details
Lead Sponsor:
Santa Chiara Hospital
Treatments:
Docetaxel
Prednisone